Recently, [68Ga]Ga-NeoB (formerly known as NeoBOMB1) was developed, a novel 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetra acetate (DOTA)-coupled bombesin-based GRPR antagonist, which showed a high affinity for GRPR (IC50 = 1.17 ± 0.06 nM (Nock et al., 2017)) and high tumor uptake in preclinical studies in a xenograft mouse model (30.7 ± 3.9%ID/g 4 h post injection (p.i.)in PC3 tumor-bearing mice) accompanied by an good in vivo stability (5 min p.i. > 95% intact, 30 min p.i. > 90% intact) (Nock et al., 2017). This evidence concerns the gene GRP and neoplasm.